A study led by researchers at Karolinska Institutet found no evidence to suggest that GLP-1 analogs, popular drugs used to treat diabetes and obesity, increase the risk of thyroid cancer. The study, published in The BMJ, analyzed data from about 145,000 patients treated with GLP-1 analogs and 290,000 patients treated with another diabetes drug. Results indicated that GLP-1 treatment was not associated with an increased risk of thyroid cancer. While certain subtypes of thyroid cancer were not studied, the findings provide strong support that GLP-1 analogs are safe in terms of thyroid cancer risk for a broad patient population.
Source link
Popular diabetes drugs do not increase thyroid cancer risk, study suggests
